Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174732 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
A Phase 2 study, sponsored by Amphastar Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01174732 is a Phase 2 study that has completed, run by Amphastar Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT01174732, a Phase 2 study, has completed, sponsored by Amphastar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of A006, from a select dose-range for future clinical PK/PD and Phase III studies. This study is to be conducted in generally healthy, adult subjects who have mild-to-moderate persistent asthma for at least 6 months prior to Screening.
Interventions
- DRUG Placebo
- DRUG albuterol inhalation powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174732
The ClinicalTrials.gov registry entry for NCT01174732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amphastar Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01174732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174732 about?
NCT01174732 is a clinical study titled "Dose-Ranging Study of A006 DPI, in Adult Asthma Patients". This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of A006, from a select dose-range for future clinical PK/PD and Phase III stud...
What is the current status of trial NCT01174732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2010-07. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01174732?
The interventions under investigation include: Placebo (DRUG), albuterol inhalation powder (DRUG).
Who is sponsoring clinical trial NCT01174732?
This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.